Folcyteine Tablet
NDC Package 59088-795-05
Package Information
Folcyteine (multivitamin) tablets is a medication a multivitamin product used to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy. This formulation utilizes a tablet delivery system. Marketed by Puretek Corporation, this product is identified by NDC 59088-795.
Identification & Billing
Clinical Specifications
- Antidote - [EPC] (Established Pharmacologic Class)
- Antidote for Acetaminophen Overdose - [EPC] (Established Pharmacologic Class)
- Blood Coagulation Factor - [EPC] (Established Pharmacologic Class)
- Calcium - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cations, Divalent - [CS]
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Increased Coagulation Factor Activity - [PE] (Physiologic Effect)
- Increased Glutathione Concentration - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Mucolytic - [EPC] (Established Pharmacologic Class)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Phosphate Binder - [EPC] (Established Pharmacologic Class)
- Phosphate Chelating Activity - [MoA] (Mechanism of Action)
- Reduction Activity - [MoA] (Mechanism of Action)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
- Vitamin D - [CS]
- Vitamin D - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 59088 - Puretek Corporation
- 59088-795 - Folcyteine
- 59088-795-05 - 1 TUBE in 1 CARTON / 22 mL in 1 TUBE
- 59088-795 - Folcyteine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (59088-795). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 59088-795-05 identifies a specific commercial package of 1 tube in 1 carton / 22 ml in 1 tube of Folcyteine, a human prescription drug labeled by Puretek Corporation. This tablet is formulated for oral use and contains acetylcysteine; calcium citrate; cholecalciferol; folic acid; magnesium citrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Puretek Corporation on September 14, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is a multivitamin product used to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy. Vitamins are important building blocks of the body and help keep you in good health.
How is this Puretek Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 59088079505. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.